Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aims: This meta‐analysis was performed to provide an update on the efficacy and safety of dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus ( T2DM ). Methods: We conducted a search on MEDLINE , Embase and Cochrane Collaborative database for randomized controlled trials ( RCTs ) of DPP ‐4 inhibitors and metformin as initial combination therapy or as monotherapy in patients with T2DM by the end of December 2012, using the key words ‘alogliptin’, ‘dutogliptin’, ‘linagliptin’, ‘saxagliptin’, ‘sitagliptin’, ‘vildagliptin’ and ‘metformin’. RCTs were selected for meta‐analysis if (1) they were RCTs comparing DPP ‐4 inhibitors plus metformin as initial combination therapy or DPP ‐4 inhibitor monotherapy to metformin monotherapy, (2) duration of treatment was ≥12 weeks and (3) reported data on haemoglobin A1c ( HbA1c ) change, fasting plasma glucose ( FPG ) change, weight change, adverse cardiovascular ( CV ) events, hypoglycaemia or gastrointestinal adverse events ( AEs ). Results: A total of eight RCTs were included. Compared with metformin monotherapy, DPP ‐4 inhibitors monotherapy was associated with lower reduction in HbA1c level [weighted mean differences ( MD ) = 0.28, 95% confidence intervals ( CIs ) (0.17, 0.40), p < 0.00001], lower reduction in FPG level [ MD = 0.81, 95% CI (0.60, 1.02), p <0.00001], lower weight loss [ MD = 1.51, 95% CI (0.89, 2.13), p < 0.00001], but lower risk of adverse CV events [risk ratio ( RR ) = 0.36, 95% CI (0.15, 0.85), p = 0.02], lower risk of hypoglycaemia [ RR = 0.44, 95% CI (0.27, 0.72), p = 0.001] and lower risk of gastrointestinal AEs [ RR = 0.63, 95% CI (0.55, 0.70), p <0.00001]. Compared with metformin monotherapy, DPP ‐4 inhibitors plus metformin as initial combination therapy was associated with higher reduction in HbA1c level [ MD = −0.49, 95% CI (−0.57, −0.40), p < 0.00001], higher reduction in FPG level [ MD = −0.80, 95% CI (−0.87, −0.74), p < 0.00001], lower weight loss [ MD = 0.44, 95% CI (0.22, 0.67), p = 0.0001]; but was not associated with a further reduction in adverse CV events [ RR =0.54, 95% CI (0.25, 1.19), p = 0.13], nor the higher risk of hypoglycaemia [ RR = 1.04, 95% CI (0.72, 1.50), p = 0.82], nor the prolonged risk of gastrointestinal AEs [ RR = 0.98, 95% CI (0.88, 1.10), p = 0.77]. Conclusions: DPP ‐4 inhibitors, which are safe and effective in controlling the blood glucose, may possibly decrease the risk of CV events in patients with T2DM . It could be a credible alternative for T2DM patients who, for some reason, cannot use metformin, or are in high risk of CV exposure. High‐quality, large sample and long‐term follow‐up clinical trails are needed to confirm the long‐term conclusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
A comparison of methods to detect publication bias in meta‐analysis
Macaskill, P., Walter, S. D., & Irwig, L. (2001) · Statistics in Medicine · doi:10.1002/sim.698 · Cited by 1,286 · cited 1×
“To assess the potential confounding effect of heterogeneity, subgroup analyses were performed, stratifying specific drugs or trial characteristics and data from specific population whenever possible [8].”
MethodGoldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Understanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Cai, X., Gao, X., Yang, W., Han, X., & Ji, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0493-2 · Cited by 47
Metadata
- Authors
- Wu, D., Li, L., & Liu, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-07-16
- Volume
- 16
- Issue
- 1
- Pages
- 30-37
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1981713709
- Cited by
- 130
- References
- 4
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis. https://app.cochat.ai/papers/10.1111/dom.12174
- The paper
- Wu, D., Li, L., & Liu, C. (2014). Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.